
Please try another search
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
James S. MacDonald | - | - | Member of Scientific Advisory Board |
Robert Taylor Nelsen | 63 | 2010 | Non-Executive Chairman |
Li Chen | 62 | 2010 | Founder, CEO & Executive Director |
Bennett M. Shapiro | 85 | - | Member of Scientific Advisory Board |
Yiu Wa Tsui | 75 | 2018 | Independent Non-Executive Director |
Catherine D. Strader | 70 | - | Member of Scientific Advisory Board |
Yiu Leung Cheung | 65 | 2023 | Independent Non-Executive Director |
Yi Zhang | 49 | 2018 | Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review